Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay.
about
Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein.Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infectionDownsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potencyRole of the simian virus 5 fusion protein N-terminal coiled-coil domain in folding and promotion of membrane fusion.Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms.Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures.Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infectionDiscovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.Virus entry: molecular mechanisms and biomedical applications.Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses.In search of a small-molecule inhibitor for respiratory syncytial virus.A generic screening platform for inhibitors of virus induced cell fusion using cellular electrical impedanceMolecular mechanism of respiratory syncytial virus fusion inhibitors.Respiratory syncytial virus entry inhibitors targeting the F protein.Phosphatidylglycerol provides short-term prophylaxis against respiratory syncytial virus infection.Targeting RSV with vaccines and small molecule drugs.RNA interference as a potential therapeutic treatment for inflammation associated lung injury.The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation.Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus.The human respiratory syncytial virus matrix protein is required for maturation of viral filaments.Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusionExpression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps.Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function.Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirusRAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein functionThe respiratory syncytial virus fusion protein targets to the perimeter of inclusion bodies and facilitates filament formation by a cytoplasmic tail-dependent mechanism.The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion.Sequence-dependent dynamical instability of the human prion protein: a comparative simulation study.Inhibition of respiratory viruses by nasally administered siRNA.
P2860
Q24815873-E8D76965-F429-4BED-8B6D-ED707E476CCBQ33591425-9BA595E3-0507-48C6-9548-9BD0DC64D11EQ33602739-BDE386D1-A79C-4EDA-892F-08EAB9F76A65Q33717024-98AF4EF2-8615-441A-A5F0-FC46DAAC560AQ33836560-2B74B2FC-968A-4071-86C8-9271D72873A1Q34057989-2EA12CE5-DF1A-4F32-AB20-ABC25569EA3BQ34082711-7ED0DE8D-B9B8-4A9B-983C-96621A519857Q35160026-559C43B6-D6B4-441F-AA73-29F8D345F1DAQ35559775-9F3DEA47-95CF-4BD7-BF80-AB246D90D026Q35712985-C25F7FCA-AA56-42D4-A79C-0537D87914C0Q35867285-10EA17C0-0949-484C-936D-FDDCEA638FC2Q35917503-F18D8AAD-A5C2-4D6D-8E95-60D19C460248Q35956838-E42E9CCB-C83B-406E-91FD-7F9C0AE3B87DQ36517337-F09865B4-7BD7-421A-8A26-35CF4C928A60Q36586879-67840F17-DDDE-4799-8C6D-C20C9856D50AQ37002647-3DDD4646-A254-4A0A-9805-C0C8CFAD6CADQ37328584-BDCA83C2-CA22-4495-9EC9-1351C623731CQ37349912-EE975F11-DE8A-4292-8B31-81800900E900Q37415410-38B20DE3-19CC-438A-8F4A-B429E8CA3A58Q38742141-470F4A47-5B7D-4162-9B2E-E1A450157316Q39399605-BB6A7D02-B533-4D17-9F67-7DE64A97CECBQ39697277-DD93CF5D-1875-4857-94B6-57E11150A39EQ40123601-8F269A16-B054-407A-AD0D-F9957FC23433Q40275833-36E4271F-04B1-403E-9FAE-B8CAB4CD6A94Q41040045-396263D0-CE92-4942-9117-AD71BE39B021Q42248771-91D1BB31-EB2F-4BE2-9AF9-3E1BE596D659Q42253000-84832022-2289-4A82-823B-F9CDD988CD73Q45323698-6A68AE23-9F64-416D-A70B-B331D337A22BQ47861173-CE86486A-810A-4A43-8F17-8C6EEBAEB663Q47874231-793D6E58-FC9A-4966-B621-DFE7E4B81050
P2860
Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Structural characterization of ...... d a syncytium formation assay.
@en
Structural characterization of ...... d a syncytium formation assay.
@nl
type
label
Structural characterization of ...... d a syncytium formation assay.
@en
Structural characterization of ...... d a syncytium formation assay.
@nl
prefLabel
Structural characterization of ...... d a syncytium formation assay.
@en
Structural characterization of ...... d a syncytium formation assay.
@nl
P2093
P50
P1433
P1476
Structural characterization of ...... d a syncytium formation assay.
@en
P2093
Angela Luttick
Anthony Mason
Jayne Sullivan
Jenny McKimm-Breschkin
Lynne J Lawrence
Melinda Lowe
Rachel Cameron
Simon P Tucker
P304
P356
10.1016/S0042-6822(03)00115-6
P407
P577
2003-07-01T00:00:00Z